UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

British journal of dermatology (1951), 2016-11, Vol.175 (5), p.902-911

2016

Volltextzugriff (PDF)

Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study

British journal of dermatology (1951), 2016-09, Vol.175 (3), p.487-492

2016

Volltextzugriff (PDF)

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.674-681

2018

Volltextzugriff (PDF)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1395-1406

2015

Volltextzugriff (PDF)

Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasis

Journal of the European Academy of Dermatology and Venereology, 2020-01, Vol.34 (1), p.39-46

2020

Volltextzugriff (PDF)

Risk of periodontitis in patients with psoriasis and psoriatic arthritis

Journal of the European Academy of Dermatology and Venereology, 2017-02, Vol.31 (2), p.288-293

2017

Volltextzugriff (PDF)

Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study

British journal of dermatology (1951), 2016-09, Vol.175 (3), p.493-500

2016

Volltextzugriff (PDF)

Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis

British journal of dermatology (1951), 2019-11, Vol.181 (5), p.976-982

2019

Volltextzugriff (PDF)

Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab

British journal of dermatology (1951), 2018-05, Vol.178 (5), p.1064-1071

2018

Volltextzugriff (PDF)

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-07, Vol.31 (7), p.1196-1207

2017

Volltextzugriff (PDF)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study

Journal of the European Academy of Dermatology and Venereology, 2016-10, Vol.30 (10), p.1753-1759

2016

Volltextzugriff (PDF)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-06, Vol.31 (6), p.1004-1013

2017

Volltextzugriff (PDF)

掌跖脓疱病患者中的斑片状银屑病

British journal of dermatology (1951), 2019-11, Vol.181 (5), p.e141-e141

2019

Volltextzugriff (PDF)

Plaque psoriasis in patients with palmoplantar pustulosis

British journal of dermatology (1951), 2019-11, Vol.181 (5), p.e129-e129

2019

Volltextzugriff (PDF)

Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study

Journal of the European Academy of Dermatology and Venereology, 2015-06, Vol.29 (6), p.1114-1120

2015

Volltextzugriff (PDF)

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

Journal of the European Academy of Dermatology and Venereology, 2017-04, Vol.31 (4), p.679-685

2017

Volltextzugriff (PDF)

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

British journal of dermatology (1951), 2017-12, Vol.177 (6), p.1537-1551

2017

Volltextzugriff (PDF)

The association between psoriasis and coeliac disease

British journal of dermatology (1951), 2017-12, Vol.177 (6), p.e329-e330

2017

Volltextzugriff (PDF)

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)

Journal of the European Academy of Dermatology and Venereology, 2017-01, Vol.31 (1), p.107-113

2017

Volltextzugriff (PDF)

Corrigendum: Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasis

Journal of the European Academy of Dermatology and Venereology, 2020-09, Vol.34 (9), p.2156-2156

2020

Volltextzugriff (PDF)

Limited association between scalp psoriasis and psoriatic arthritis severity and treatment response

Clinical and experimental rheumatology, 2017-01, Vol.35 (1), p.141

2017

Volltextzugriff (PDF)

Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study

British journal of dermatology (1951), 2015-08, Vol.173 (2), p.471-479

2015

Volltextzugriff (PDF)

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

Journal of the European Academy of Dermatology and Venereology, 2018-01, Vol.32 (1), p.68-72

2018

Volltextzugriff (PDF)

Hereditary Angioedema in Swedish Adults: Report From the National Cohort

Acta dermato-venereologica, 2016, Vol.96 (4), p.540-545

2016

Volltextzugriff (PDF)

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-02, Vol.31 (2), p.323-332

2017

Volltextzugriff (PDF)

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(118)

Publikationsform

Artikel
(102)
Tagungsberichte
(24)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasis

Risk of periodontitis in patients with psoriasis and psoriatic arthritis

Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study

Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis

Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

掌跖脓疱病患者中的斑片状银屑病

Plaque psoriasis in patients with palmoplantar pustulosis

Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

The association between psoriasis and coeliac disease

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)

Corrigendum: Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasis

Limited association between scalp psoriasis and psoriatic arthritis severity and treatment response

Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

Hereditary Angioedema in Swedish Adults: Report From the National Cohort

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Suchergebnisse filtern